MedTrace Logo

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

NCT03653052 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-04-24

No results posted yet for this study

Summary

Patients with cancer are increasingly being treated with drugs designed to modulate the response of their immune system, broadly to boost their body's defences against cancer. However, there is an unmet need to identify which patients are unlikely to benefit. Deciding on benefit from therapy uses standard imaging methods (e.g. CT scans), which can take time (months) whereas DNA in the bloodstream could be measured more rapidly.

The main aim of this study is to assess whether changes in the level of circulating tumour DNA (ctDNA) can quickly determine a patients response. This would enable patients to change therapies more quickly if they are not responding and reduce exposure to unnecessary side effects.

Conditions

  • Oesophageal Cancer

Interventions

DRUG

Durvalumab

Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Simon C Pacey, MD

    lead OTHER

Principal Investigators

  • Simon Pacey · Cambridge University Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2021-11-11
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03653052 on ClinicalTrials.gov